Shah Divya, Young Kristen
Internal Medicine, University of Arizona College of Medicine - Phoenix, Phoenix, USA.
Rheumatology, University of Arizona College of Medicine - Phoenix, Phoenix, USA.
Cureus. 2023 Dec 3;15(12):e49867. doi: 10.7759/cureus.49867. eCollection 2023 Dec.
Pembrolizumab, a humanized monoclonal anti-programmed cell death protein 1 (PD1) antibody, has shown efficacy in various malignancies. This article presents a case of stage III squamous cell carcinoma of the bladder treated with pembrolizumab, resulting in the development of a rare overlap syndrome known as myocarditis, myositis, and myasthenia gravis (IM3OS). While immune checkpoint inhibitors like pembrolizumab demonstrate notable antitumor activity, they also pose the risk of severe immune-related adverse events. The case underscores the importance of the early detection of IM3OS and the potential dangers associated with delayed diagnosis, offering valuable insights for healthcare providers managing patients on pembrolizumab therapy.
帕博利珠单抗是一种人源化抗程序性细胞死亡蛋白1（PD1）单克隆抗体，已在多种恶性肿瘤中显示出疗效。本文介绍了一例接受帕博利珠单抗治疗的III期膀胱鳞状细胞癌病例，该病例导致了一种罕见的重叠综合征，即心肌炎、肌炎和重症肌无力（IM3OS）。虽然像帕博利珠单抗这样的免疫检查点抑制剂具有显著的抗肿瘤活性，但它们也存在引发严重免疫相关不良事件的风险。该病例强调了早期检测IM3OS的重要性以及延迟诊断的潜在危险，为管理接受帕博利珠单抗治疗患者的医护人员提供了宝贵的见解。
